Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Fueled by Roivant Deal, Sumitomo Dainippon Accelerating DX as It Looks Beyond Latuda LOE
July 9, 2021
- FDA Updates Aduhelm Label to Only Cover MCI, Mild Alzheimer’s
July 9, 2021
- KM Biologics Expects PIII Launch for COVID-19 Vaccine This Autumn: President
July 8, 2021
- Edirol, Generic Drugs All Now Face Supply Curbs as Nichi-Iko Woes Spill Over
July 8, 2021
- Bristol Myers Kicks Off COVID-19 Inoculation Program, Eliminates Cost Burden on Employees
July 8, 2021
- Tecentriq Filed in Japan as Adjuvant Therapy for NSCLC: Chugai
July 8, 2021
- Bayer’s Vitrakvi Now Available in Japan for NTRK-Positive Solid Tumors
July 8, 2021
- Japan Ethical Drug Sales Up 6.8% in May: Crecon
July 8, 2021
- 34 Japan Pharma Execs Earn 100 Million Yen or More in FY2020, Top 3 at Takeda
July 7, 2021
- 26 Japan Drug Makers’ Annual Pay Averages 8.21 Million Yen, 5 Firms Top 10 Million Yen Mark
July 7, 2021
- Keytruda Retains Top Spot in Japan Drug Ranking in June: Encise
July 7, 2021
- Sosei Teams Up with InveniAI on GPCR-Targeted Drug Discovery
July 7, 2021
- Astellas Revamping Sales Organization as Product Mix Shifts towards Specialty Area: CEO
July 6, 2021
- CEO Says Astellas Pivoting to Specialty Drugs, Going Global: Full Interview
July 6, 2021
- Sagent Jettisons Camostat Mesilate for COVID-19 after PII Miss: Nichi-Iko
July 6, 2021
- Reps’ Face-to-Face Meetings Up 76.1% YOY in May: Intage
July 6, 2021
- All Ranitidine Tablet Drugs to Be Discontinued in Japan over Carcinogen Woes
July 5, 2021
- Astellas Begins COVID-19 Vaccination Program
July 5, 2021
- Ivermectin to Enter 1st Company-Sponsored COVID-19 Trial in Japan
July 2, 2021
- 3 Major Wholesalers, 7 Employees Found Guilty in Bid-Rigging Trial
July 2, 2021
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…